Lupin's foray into diagnostics appears a calculated risk

The under-performing pharma company's foray into a competitive services business like diagnostics may seem counter-intuitive, as Lupin has been facing many challenges in its US business, including pricing pressure, increased competitive intensity, compliance and drug settlement costs.

from Economic Times https://ift.tt/3pNSPgl